- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05848336
The Gluten-Casein-free Diet in Children With Autism: A Clinical Results of the Ophthalmic and Behavioral Manifestations
Effect of Gluten-free, Casein-free Diet in Children With Autism
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Autism spectrum disorder (ASD) is a common condition. ASD is a heritable illness characterized by early-onset differences in interaction, communication, sensory atypicality, and stereotyped behaviors. Recent studies suggest a link between elimination diets and severity of autistic behaviors. The etiology of ASD has been still uncertain. Therefore, elucidating the underlying pathology may assist in risk assessment and facilitate process management. Non-harmful and existing evidence for the diet's benefits in ASD must be elucidated.
Primary Study Objective:
To assess the effect of a GFCF diet on variables autism index, stereotyped behaviors, communication, social interaction associated with ASD.
The pupillary response can be utilized to anticipate neurological and physiological activities under the surface. Changes in light trigger the pupil response, which adjusts the amount of brightness falling on the retina by instinctively constricting or dilating the pupil. Atypical pupil size has been linked to abnormal autonomic function in people with ASD. Disturbances in autonomic functions may also lead to differences in the corneal reflex. This study aimed to obtain more data on the behavioral symptoms and ophthalmic measurements of gluten-free casein-free (GFCF) on ASD. In addition, normal development children and children with autism may differ in facial morphology. This study also evaluates the effect of GFCF diet on IPD distance.
Secondary Objectives:
To assess the role of GFCF diet in the manifestation of opthalmic measurements such as pupil size, corneal reflex and IPD.
30 children with ASD were enrolled in a 8-weeks prospective GFCF diet treatment study. In the study, a single group was evaluated with measurements before and after dietary intervention.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
İstanbul, Turkey, 34672
- Uskudar University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Informed consent / Assent, as applicable must be signed prior to executing any study related procedure
- Children, male or female, 2 to 11 years old (inclusive)
- Confirmed diagnosis of ASD according to the DSM-IV Symptom Checklist
- Ability to maintain a gluten- and casein-free diet during the study
Exclusion Criteria:
- Cardiovascular, psychiatric, autoimmune, cancer, etc. children with secondary different disease
- Children with any drug use
- Children currently receiving treatment with any alternative medical methods (eg.hyperbaric).
- Children with a diagnosis of celiac disease
- Children who have received any dietary treatment before
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Gluten Free Casein Free Diet
Foods containing gluten (pasta, bread, etc.), casein (unfermented dairy products), and their disguised sources have been eliminated from the nutrition program.
Also, packaged foods (chocolate, crackers, etc.) containing additives such as artificial preservatives, food coloring, and sweeteners that create a tendency to consume in children were avoided from the nutrition program.
Goat milk contains type A2 casein, and most of the casein is digested in fermented dairy products.
In order to increase calcium intake, the consumption of some foods (dill, kale, spinach, chard, arugula, broccoli, parsley, legumes, nuts, tahini, etc.) has been increased.
Elimination was done gradually, considering nervousness, anxiety, etc., due to the effects of opioid mechanisms of action and gastrointestinal system symptoms.
|
Thirty children with autism were evaluated before the diet (Pre-Test) and after 8 weeks of dietary intervention (Post-Test).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gilliam Autism Rating Scale 2 (GARS-2)
Time Frame: 8 weeks
|
Based on DSM-IV autism diagnostic criteria, GARS-2 is a behavior checklist for children and teenagers aged 3 to 22.
The three subscales of the scale are communication, social interaction, and stereotypical behavior.
Each subscale contains 14 items that are scored on a four-point scale (0: Never observed, 1: Rarely observed, 2: Sometimes observed, 3: Often observed).
The total score obtained from the scale is converted into standard scores, and an OBI score is obtained.
An OBI score of 85 and above indicates a high probability of having ASD, a score between 70-84 indicates a medium probability, and a score of 69 and below indicates a low probability.
|
8 weeks
|
|
Weight (kg)
Time Frame: 8 weeks
|
Body weight was measured in kilograms.
|
8 weeks
|
|
Body mass index
Time Frame: 8 weeks
|
Body mass index (BMI)=weight/(height)^2
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The pupil measurements
Time Frame: 8 weeks
|
The measurements of both groups were taken from a distance of 1 meter with a binocular photo refractometer under the same conditions, without cycloplegia.
Plusoptix® A09 an measure a pupil size of 4.0-8.0
mm in 0.1 mm steps.
Eccentric photorefraction is used as a measurement basis.
The device provides convenience in terms of pediatric evaluation with its remarkable features.
The pupil measurements were performed by an ophthalmologist in the outpatient clinical unit.
The brightness level in the room was controlled via the lux meter application.
Pupil size (mm) was measured at least three times after each participant was left in a room with a light level of 8 cd/m2 for 2 minutes.
The average value of 3 consecutive consistent measurements was recorded.
|
8 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UskudarUGFCFAUTISM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorder
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Istituto Clinico HumanitasRecruitingAutism | Autism Spectrum Disorder (ASD) | Autism DisorderItaly
-
The Children's Hospital of Zhejiang University...Not yet recruitingAutism | Autism Spectrum Disorder (ASD)China
-
Poznan University of Physical EducationCompletedAutism | Autism Spectrum Disorder (ASD)Poland
-
Greater Atlanta Integrative PediatricsRecruitingAutism Spectrum Disorder | Autism | ASD | Autism Spectrum Disorder (ASD)United States
-
Adia Med of Winter Park LLCRecruitingAutism Spectrum Disorder | Autism | ASD | Autism Spectrum Disorder (ASD)United States
-
Poznan University of Physical EducationNational Science Centre, PolandCompletedAutism Spectrum Disorder | ASD | Autism Spectrum Disorder High-Functioning | Autism SpectrumPoland
-
Blinklab LimitedRecruitingAutism Spectrum Disorder | Autism | Neurodevelopmental Conditions | Autism Spectrum Disorder (ASD)United States
-
National Cheng-Kung University HospitalCompletedAutism Spectrum Disorder (ASD) | Autism Spectrum Disorder High-FunctioningTaiwan
-
Stanford UniversityJohn and Marcia Goldman FoundationNot yet recruitingAutism | Autism Spectrum Disorder (ASD)United States
-
Stanford UniversityCalifornia Department of Developmental ServicesActive, not recruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
Clinical Trials on Gluten Free Casein Free Diet
-
Karadeniz Technical UniversityThe Scientific and Technological Research Council of TurkeyCompletedNutrition | Autism Spectrum Disorder (ASD)Turkey (Türkiye)
-
Center for Autisme, DenmarkNorway: Bo Nils og Seim Family Settlement; The Robert Luff Foundation, United... and other collaboratorsCompletedAutism | Autism Spectrum Disorder (ASD)
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...UnknownCeliac DiseaseItaly
-
Massachusetts General HospitalNutricia North AmericaCompletedAutism | Gastrointestinal SymptomsUnited States
-
Sahlgrenska University Hospital, SwedenCompletedIrritable Bowel SyndromeSweden
-
University Hospital, Clermont-FerrandInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement and other collaboratorsRecruitingAnkylosing SpondyloarthritisFrance
-
Massachusetts General HospitalTerminated
-
Acibadem UniversityCompletedHashimoto Disease | Hashimoto ThyroiditisTurkey
-
University of CopenhagenRigshospitalet, DenmarkCompletedThe Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With CISMultiple Sclerosis | Clinically Isolated Syndrome | Optic NeuritisDenmark
-
University Hospital of North NorwayThe Norwegian Coeliac Society; The Gastrointestinal Research Foundation, University...Completed